应用雷替曲塞经肝动脉化疗栓塞治疗中晚期原发性肝癌的临床疗效

目的 应用雷替曲塞与碘化油混合乳剂行TACE治疗中晚期原发性肝癌,观察其临床效果及安全性。方法 对我院收治的不能手术切除的原发性中晚期肝癌患者80例的临床资料进行研究,按治疗方案分为治疗组与对照组,每组40例。观察两组患者近期(术后1个月)疗效,包括中位疾病进展时间及1年、2年生存率、患者血清肿瘤标记物(AFP、CA19-9)、转氨酶及胆红素变化,不良反应发生情况。结果 治疗组术后3个月RR、DCR均高于对照(P<0.01);治疗组的1年与2年生存率分别为81.6%、57.5%,显著高于对照组的67.0%和35.9%(P<0.05);治疗组中位生存期为11.6个月,高于对照组7.3个月(P<0.05);治疗组术后1个月AFP、CEA、转氨酶、胆红素水平下降的例数多于对照组(P<0.05);两组间不良反应发生率比较显示无统计学意义(P>0.05)。结论 应用雷替曲塞与碘化油经肝动脉内栓塞治疗中晚期原发性肝癌临床效果显著,安全性良好。

Clinical efficacy of raltitrexed by transcatheter arterial chemoembolization n the treatment of advanced primary liver cancer

Objective To investigate the clinical efficacy and safety of the transcatheter arterial chemoembolization with raltitrexed and lipiodol emulsion in the treatment of advanced primary liver cancer.Methods The clinical data of 80 patients with inoperable primary and advanced liver cancer admitted to our department were studied. According to the treatment plan, they were divided into the treatment group and the control group, with 40 patients in each group. The short-term (1 month after surgery) efficacy of the two groups of patients was observed, including the median disease progression time, 1-year and 2-year survival rate, serum tumor markers (AFP, CA19-9), changes of transaminase and bilirubin, and adverse reactions.Results Three months after operation, RR and DCR in the treatment group were higher than those in the control group (P<0.01); the 1-year and 2-year survival rates in the treatment group were 81.6% and 57.5%, respectively, which were significantly higher than those in the control group (67.0% and 35.9%, respectively, P<0.05); median survival time in the treatment group was 11.6 months, higher than 7.3 months in the control group (P<0.05); the number of AFP, CEA, transaminase and bilirubin decreased in the treatment group 1 month after operation was higher than that in the control group (P<0.05); the comparison of the incidence of adverse reactions between the two groups showed no statistical significance (P<0.05).Conclusion The clinical efficacy and safety of retetroxel and iodized oil in the treatment of advanced primary liver cancer by intra-arterial embolization were significant.